Supporting Information for

Uniform Magnesium Silicate Hollow Spheres as High Drug-Loading Nanocarriers for Cancer Therapy with Low Systemic Toxicity

Baixiang Wang,*,a Weiyan Meng,b Ming Bi,c Yuxin Ni,b Qing Cai,b and Jingyun

Wang**,a

^a Department of Prosthodontics, School of Stomatology, Jilin University, Changchun, 130021 (P. R. China).

Fax: (+86) 0431-88796018 Tel: (+86) 0431-88796018

E-mail: baixiangwang1@gmail.com; jlccjingyun@sina.com

^b Department of Implantology, School of Stomatology, Jilin University, Changchun, 130021 (P. R. China).

^c Department of Comprehensive Treatment, School of Stomatology, Jilin University, Changchun, 130021 (P. R. China).




Figure S1. TEM image of SiO₂ colloidal spheres.




Figure S2. Nitrogen adsorption-desorption isotherms of MgSiO₃ hollow spheres (a) and pore size distribution from adsorption branch (b).




Figure S3. Quantification of DOX loading at different pH values upon different DOX concentrations (a) and histogram analysis with three independent experiments (b). Higher drug loading was achieved at increased pH.




Figure S4. Amplificatory images: without nanoparticles (a) and with nanoparticles (b).




Figure S5. Time-dependent biodistribution of MgSiO₃ hollow spheres in mice.

Table S1. Exact value of hemolysis percentage upon MgSiO₃ hollow spheres with different concentrations.

Concentrations (µg MgSiO ₃ mL ⁻¹)	Value of hemolysis (%)	
D. I. Water	100	
PBS	0	
12.5	-0.012	
25	0.136	
50	0.2593	
100	0.509	
200	0.781	

Table S2. Pathological inflammatory responses of various viscera 30 d after intravenous administration of MgSiO₃ hollow spheres.

Samples	Grade of	Lymphocytes	Macrophages	Neutrophilis	Eosinophils
	Inflammation				
Heart	Low	+-	+-	+-	+-
Liver	Low	+	+	+	+-
Spleen	Low	+	+	+	+-
Lung	Low	+-	+-	+-	+-
Kidney	Low	+-	+-	+-	+-

Table S3. Hematology analysis and blood biochemical assay 30 days after intravenous administration of MgSiO₃ hollow spheres.

Test	Unit	Control group (mean ± sd)	Treatment group (mean ± sd)
blood cell count (WBC)	$\times 10^9/L$	9.6±2.1	9.4 ± 1.6
red cell count (RBC)	$\times~10^{12}/L$	9.8 ± 2.7	9.1 ± 2.3
hemoglobin (HGB)	g/L	167.7 ± 21.8	172.1 ± 34.8
mean corpuscular hemoglobin	pg	16.3 ± 1.9	16.1 ± 4.2
(MCH)			
mean corpuscular hemoglobin	g/L	330 ± 25.4	320 ± 27.9
concentration (MCHC)			
alanine aminotransferase	U/L	49.5 ± 6.5	45.6 ± 8.4
(ALT)			
aspartate aminotransferase	U/L	152.4 ± 26.5	165.3 ± 33.4
(AST)			
blood urea nitrogen (BUN)	$\times~10^6/\mu L$	7.9 ± 1.3	8.7 ± 2.1
plasma creatinine (CRE)	$\times~10^3/\mu L$	20.8 ± 2.8	25.6±3.7